Bridget E. Bunner

Array ( [id] => 13793413 [patent_doc_number] => 20190010245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => MECHANO-ACTIVATED CONTROL OF GENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/141491 [patent_app_country] => US [patent_app_date] => 2018-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16141491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277303 [patent_doc_number] => 20190135936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => Anti-Jagged Antibodies and Methods of Use [patent_app_type] => utility [patent_app_number] => 16/136478 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16136478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043535 [patent_doc_number] => 20190077874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS [patent_app_type] => utility [patent_app_number] => 16/129917 [patent_app_country] => US [patent_app_date] => 2018-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14886 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268867 [patent_doc_number] => 20200270354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => COMBINATION TREATMENT FOR CANCER [patent_app_type] => utility [patent_app_number] => 16/646836 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17015229 [patent_doc_number] => 11084856 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Interleukin-4 receptor-binding fusion proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/125075 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 17 [patent_no_of_words] => 17100 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16125075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17649688 [patent_doc_number] => 11352402 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => Interleukin-4 receptor-binding fusion proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/125566 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 15 [patent_no_of_words] => 14307 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16125566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986525 [patent_doc_number] => 20190062420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => FC Gamma RIII Binding Fibronectin Type III Domains, Their Conjugates and Multispecific Molecules Comprising Them [patent_app_type] => utility [patent_app_number] => 16/111360 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618229 [patent_doc_number] => 20180360666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => Hemostatic Textile [patent_app_type] => utility [patent_app_number] => 16/111362 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16108493 [patent_doc_number] => 20200206269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => PRODUCTION OF ENUCLEATED RED BLOOD CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/641203 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -94 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16641203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391432 [patent_doc_number] => 20230159650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => COMPOSITION FOR PREVENTING OR TREATING DISEASES CAUSED BY OVEREXPRESSION OF CHEMOKINE CX3CL1, CONTAINING DEATH RECEPTOR INHIBITOR AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 16/637357 [patent_app_country] => US [patent_app_date] => 2018-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13574995 [patent_doc_number] => 20180339046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/057217 [patent_app_country] => US [patent_app_date] => 2018-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16057217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19368487 [patent_doc_number] => 12060561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Use of constitutively active variants of growth factor receptors as selection markers for the generation of stable producer cell lines [patent_app_type] => utility [patent_app_number] => 16/636622 [patent_app_country] => US [patent_app_date] => 2018-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3956 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16215127 [patent_doc_number] => 10730925 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same [patent_app_type] => utility [patent_app_number] => 16/045848 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 44 [patent_no_of_words] => 26301 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16045848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15934165 [patent_doc_number] => 20200158716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => CELL ATLAS OF HEALTHY AND DISEASED BARRIER TISSUES [patent_app_type] => utility [patent_app_number] => 16/631898 [patent_app_country] => US [patent_app_date] => 2018-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 161759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -93 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993515 [patent_doc_number] => 20200172628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => ANTIBODY MOLECULES TO CD73 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/625293 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16625293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586549 [patent_doc_number] => 20180344823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/014419 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102437 [patent_doc_number] => 11542312 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => IL-2 superagonists in combination with anti-PD-1 antibodies [patent_app_type] => utility [patent_app_number] => 16/012733 [patent_app_country] => US [patent_app_date] => 2018-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 41826 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16012733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622103 [patent_doc_number] => 20180362603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/010805 [patent_app_country] => US [patent_app_date] => 2018-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16010805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460797 [patent_doc_number] => 10844132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Neutralizing antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/008998 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 90 [patent_no_of_words] => 29588 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460797 [patent_doc_number] => 10844132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Neutralizing antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/008998 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 90 [patent_no_of_words] => 29588 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008998 [rel_patent_id] =>[rel_patent_doc_number] =>)